{"version":"1.0","provider_name":"HeimBiotek","provider_url":"https:\/\/heimbiotek.com\/ko","author_name":"HBadmin","author_url":"https:\/\/heimbiotek.com\/ko\/blog\/author\/hbadmin\/","title":"HeimBiotek, Successful Development of Companion Diagnostic for Anticancer Drug Irinotecan - HeimBiotek","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"r8kypa5JKA\"><a href=\"https:\/\/heimbiotek.com\/ko\/blog\/2018\/06\/01\/news02\/\">\ud558\uc784\ubc14\uc774\uc624\ud14d, \ud56d\uc554\uc81c \uc774\ub9ac\ub178\ud14c\uce78 \ub3d9\ubc18\uc9c4\ub2e8 \uac1c\ubc1c \uc131\uacf5<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/heimbiotek.com\/ko\/blog\/2018\/06\/01\/news02\/embed\/#?secret=r8kypa5JKA\" width=\"600\" height=\"338\" title=\"&#8220;HeimBiotek, Successful Development of Companion Diagnostic for Anticancer Drug Irinotecan&#8221; &#8212; HeimBiotek\" data-secret=\"r8kypa5JKA\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/heimbiotek.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>","thumbnail_url":"https:\/\/heimbiotek.com\/wp-content\/uploads\/2018\/06\/3_sbdePlex@2x-50.jpg","thumbnail_width":2200,"thumbnail_height":1320,"description":"HeimBiotek, Successful Development of Companion Diagnostic for Anticancer Drug Irinotecan &nbsp;&nbsp;&nbsp;&nbsp;HeimBiotek announced on the 1st that it has successfully developed a companion diagnostic (CDx) for irinotecan, the most prescribed anticancer drug for solid tumors in cancer patients, utilizing Specific Bi-Direction-Extension (SBDE) technology. The newly developed CDx kit for irinotecan allows simultaneous detection and analysis of the heterozygous and homozygous forms of patient gene &#8216;UGT1A1&#8217; variants *6 (SNP) and *28 (TA repeat sequence variation) in a single PCR tube, a global first. Irinotecan is commonly prescribed for cancers such as gastric, lung, and colorectal cancers, but dosing and prescription must consider the patient&#8217;s genotype. Patients with genotypes that can cause adverse reactions to irinotecan may experience severe diarrhea due to damage to the intestinal mucosa post-drug administration, and in some cases, may even lead to sepsis and death. A representative from HeimBiotek explained, &#8220;Incorrect administration of irinotecan can tragically result in patients suffering fatal adverse effects from the drug they received to treat their cancer, highlighting an ironic situation.&#8221; They added, &#8220;For this reason, the US FDA and European CE recommend companion diagnostics through UGT1A1 gene analysis before prescribing irinotecan.&#8221; Furthermore, they emphasized, &#8220;HeimBiotek now offers a much simpler and cost-effective method for irinotecan companion diagnostics compared to traditional parallel experimental analysis using multiple PCR tubes or genetic sequencing methods.&#8221; This content is partially excerpted from a news article. Source: https:\/\/www.mdtoday.co.kr\/mdtoday\/index.html?no=322747"}